Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyowa Pharm., Taiyo Recall Their Theophylline Products
August 9, 2010
- Korosho Warns against Rhabdomyolysis due to ARBs
August 9, 2010
- Dr Teraoka Proposes Introduction of CU into Japan
August 9, 2010
- JGA to Expand Its Membership Base
August 9, 2010
- High Costs, Poor Communication Skills in English Cited as Japan's Major Challenges
August 9, 2010
- 23 Groups Call for Public Funding for Cervical Cancer Vaccination
August 9, 2010
- Anti-Flu Drug from Daiichi Sankyo Recommended for Approval
August 9, 2010
- Astellas Extends VelocImmune Technology License Agreement with Regeneron
August 9, 2010
- Inappropriate Disposal of Waste Material Containing Gene Recombinants Reported by Ono
August 9, 2010
- 7 New Drugs Recommended for Approval
August 9, 2010
- Shionogi to Begin PIII for Next-Generation HIV Drug by End 2010
August 9, 2010
- Kyowa Kirin's Sales in Jan.-June Up to ¥103,475 Mil. Driven by Nesp/Espo
August 9, 2010
- Greater-Strength Aricept Tab Approved in the US
August 9, 2010
- Dexrazoxane, Fomepizole to Be Developed
August 9, 2010
- Daiichi Sankyo, Kitasato Institute to Create Joint Venture for Vaccines
August 9, 2010
- Chuikyo to Discuss 1980 Notification in Earnest
August 9, 2010
- ASKA Aims at ¥50 Bil. Sales in Mid-Term Business Plan Starting FY2013
August 9, 2010
- Antiepileptic Drug E Keppra Approved: Otsuka, UCB
August 9, 2010
- Increases in Market Prices due to New Premium Not Touched by Council
August 9, 2010
- Yaz Approved for Dysmenorrhea: Bayer
August 9, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…